ライフサイエンスコーパス: constipation

1 the search terms 'Parkinson's disease' and 'constipation'.

2 7.5% for incontinence and 15.6% vs 54.0% for constipation).

3 g, heartburn, abdominal pain, diarrhoea, and constipation).

4 ausea/vomiting, pain, dyspnea, anorexia, and constipation).

5 lyethylene glycol alone in the management of constipation.

6 the use of polyethylene glycol in functional constipation.

7 aspects of fecal control (P < 0.05), except constipation.

8 colonic mucosal microbiota of patients with constipation.

9 ane production (measured in breath), but not constipation.

10 ch may be associated with the development of constipation.

11 n and significantly reduced morphine-induced constipation.

12 isits in 2012; most of these visits were for constipation.

13 problems, to delays in gastric emptying and constipation.

14 c abdominal pain, bloating gas, diarrhea and constipation.

15 ation and treatment of patients with chronic constipation.

16 eatment approaches for patients with chronic constipation.

17 mediates the prolonged effect of morphine on constipation.

18 teria, 8/20 (40%) fulfilled the criteria for constipation.

19 ive than placebo in children with functional constipation.

20 agonist, for the treatment of opioid-induced constipation.

21 n (6 months to 18 years old) with functional constipation.

22 unction' factor was distinct from functional constipation.

23 associated with delayed colonic transit and constipation.

24 with motor and non-motor symptoms, including constipation.

25 e was well tolerated with a low incidence of constipation.

26 by motor and nonmotor impairments, including constipation.

27 62 healthy women and 295 women with chronic constipation.

28 imulation (SNS) is an evolving treatment for constipation.

29 of prostaglandin E1 (PGE1) used for chronic constipation.

30 effects, including dysphoria, diuresis, and constipation.

31 and 01) involving 1276 patients with chronic constipation.

32 risks and benefits of linaclotide in chronic constipation.

33 abdominal symptoms in patients with chronic constipation.

34 depression of breathing, nausea and chronic constipation.

35 fety of linaclotide in patients with chronic constipation.

36 f linaclotide doses in patients with chronic constipation.

37 h chronic non-cancer pain and opioid-induced constipation.

38 potential treatments for age-related chronic constipation.

39 dulator of morphine-related inflammation and constipation.

40 thout major side effects such as sedation or constipation.

41 nstipation and irritable bowel syndrome with constipation.

42 aspects of fecal control (P < 0.05), except constipation.

43 its therapeutic efficacy in mouse models of constipation.

44 and contribute to the development of chronic constipation.

45 transient, IBS-like symptoms but no sign of constipation.

46 kinson's disease compared with those without constipation.

47 atitis (18%), alternating bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (

48 tion (19%), nausea (16%), fatigue (14%), and constipation (14%) as the most frequent adverse effects.

49 %] vs 6 [13%]), nausea (17 [9%] vs 5 [11%]), constipation (15 [8%] vs 1 [2%]), and insomnia (15 [8%]

50 rders (27 with irritable bowel syndrome with constipation, 15 with functional bloating, and 3 with ir

51 %] vs 10/109 [9%]), as was treatment-related constipation (16/92 [17%] vs 6/109 [6%]).

52 e of tremor (RR 7.59, 95% CI 1.11-44.83) and constipation (2.01, 1.62-2.49) was higher in those who w

53 .31), balance impairments (2.19, 1.09-4.16), constipation (2.24, 2.04-2.46), hypotension (3.23, 1.85-

54 lutamide were nausea (26 [14%] vs 33 [17%]), constipation (23 [13%] vs 25 [13%]), and arthralgia (18

55 anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and we

56 ombocytopenia (32.2%), headache (29.4%), and constipation (26.5%).

57 re grade 1-4 anorexia (33 [28%] vs 10 [8%]), constipation (29 [25%] vs 11 [9%]), hypomagnesaemia (27

58 4.9% vs 2.2% of feeding days; P < .001), and constipation (3.1% vs 2.1% of feeding days; P = .003).

59 e bowel syndrome (IBS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD

60 of 109), loss of appetite, 50.5% (49 of 97), constipation 30.4% (21 of 69), pain 30.2% (29 of 96), an

61 re predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia 21

62 (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeu

63 -five individuals with IBS (35 with IBS with constipation, 35 with IBS with diarrhea, and with 5 IBS

64 usea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%).

65 gastrointestinal toxicities (diarrhea [46%], constipation [41%], and nausea [38%]) and grade 3/4 cyto

66 (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and st

67 2%], 68 [14%], and 204 [21%], respectively), constipation (59 [6%], 75 [15%], and 173 [17%], respecti

68 n increase over placebo in both trials being constipation (6%-8% for preladenant vs 1%-3% for placebo

69 ment-related adverse event, mild to moderate constipation (6.3%) was the most common gastrointestinal

70 ory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]).

71 acebo, were nausea (8.1% and 7.5% vs. 5.1%), constipation (7.4% and 8.6% vs. 2.5%), and abdominal pai

72 rrhea, with gastrointestinal side effects of constipation, abdominal pain, and nausea.

73 Chronic constipation accounts for at least 8 million annual visi

74 cantly increased odds of maternally reported constipation (adjusted odds ratio [aOR], 2.7; 95% CI, 1.

75 ed with colonic transit before adjusting for constipation, age, body mass index, and diet; genera fro

76 de effects, such as respiratory suppression, constipation, allodynia, tolerance, and dependence, as w

77 received fecal microbiota from patients with constipation also upregulated SERT in Caco-2 cells.

78 Constipation among Asian adults was characterized by thr

79 drugs for both idiopathic and opioid-induced constipation and a new algorithm for the evaluation of p

80 irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders.

81 r old male with multiple episodes of melena, constipation and abdominal pain for one year duration is

82 However, side effects, including persistent constipation and antinociceptive tolerance, limit its cl

83 05), and discriminated between patients with constipation and controls with 94% accuracy.

84 atients suffer from gastroesophageal reflux, constipation and delayed gastric emptying.

85 y women (controls) and 25 women with chronic constipation and evaluated by 16S ribosomal RNA gene seq

86 early parasympathetic dysfunction leading to constipation and gastroparesis.

87 n-specific increased risk of IBS, dyspepsia, constipation and GERD.

88 s study, fecal microbiota from patients with constipation and healthy controls were transplanted into

89 nd fecal microbiota in patients with chronic constipation and in healthy subjects to investigate the

90 search terms: bowel dysfunction, defecation, constipation and irrigation.

91 between constipation subtypes of functional constipation and irritable bowel syndrome with constipat

92 lyethylene glycol is commonly used to manage constipation and is available with or without electrolyt

93 s will increase the diagnostic confidence of constipation and its subtypes but more studies of the va

94 associated with motility disorders inducing constipation and loss of nitrergic myenteric neurons in

95 ent of neuromodulatory techniques for severe constipation and new insights into the pathogenesis and

96 S, functional abdominal bloating, functional constipation and pelvic floor dyssynergia.

97 treatment of IBS with constipation, relieves constipation and reduces IBS-associated pain in these pa

98 g colonic motility and visceral sensation in constipation and reversing the effects of opioid induced

99 s associated with less nausea, vomiting, and constipation and with better appetite than standard trea

100 ronic constipation (including opioid-induced constipation), and visceral pain.

101 f nausea, sleep disturbance, skin reactions, constipation, and depression, with only skin reactions r

102 physical dependence, respiratory depression, constipation, and displayed no reward or aversion in CPP

103 opicapone vs placebo groups were dyskinesia, constipation, and dry mouth.

104 Physical functioning, constipation, and dyspnea were independent significant p

105 It appears that the risk of dyspepsia, constipation, and GERD are higher among those who have A

106 ry thresholds) and secondary (bowel diaries, constipation, and GIQoL [gastrointestinal quality of lif

107 tment-emergent adverse events being fatigue, constipation, and headache.

108 family history of PD or tremor, a history of constipation, and lack of smoking history.

109 o lower incidence of overall adverse events, constipation, and least trial withdrawal rate.

110 onstipation or irritable bowel syndrome with constipation, and with >2 features of impaired evacuatio

111 Fatigue, constipation, anemia, nausea, and diarrhea were the most

112 s of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pa

113 rrhea (aOR, 2.3; 95% CI, 1.5-3.6; P < .001), constipation (aOR, 1.6; 95% CI, 1.2-2.3; P < .01), and f

114 meta-analysis demonstrates that people with constipation are at a higher risk of developing Parkinso

115 nfantile colic, gastroesophageal reflux, and constipation are the most common functional gastrointest

116 (GI) dysfunctions, such as gastroparesis and constipation, are prodromal to the cardinal motor sympto

117 Children with functional constipation, based on the Rome III criteria, were given

118 discriminated healthy people from those with constipation but normal balloon expulsion time.

119 retardation, skeletal dysplasia, and severe constipation) but only borderline-abnormal thyroid hormo

120 Prader-Willi Syndrome (PWS) have symptoms of constipation, but bowel function in PWS has never been s

121 Studies were included if they assessed constipation by means of a structured questionnaire or i

122 disease compared with those without and that constipation can predate Parkinson's diagnosis by over a

123 Chronic idiopathic constipation (CC) and irritable bowel syndrome with pred

124 According to Rome criteria, chronic constipation (CC) includes functional constipation (FC)

125 ue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin, but clinica

126 d in response to a meal, in 15 patients with constipation, chronically dependent on laxatives, 5 heal

127 ithm provided to evaluate chronic idiopathic constipation (CIC) that is refractory to available laxat

128 In the adult population, the management of constipation continues to evolve as well as the understa

129 dian = 32)) were evaluated with the Rome III constipation criteria, stool diary, digital rectal exami

130 food and water intake, Smn deficiency caused constipation, delayed gastric emptying, slow intestinal

131 In clinical practice, assessment of constipation depends on reliability, consistency and fre

132 GI symptoms were based on maternal report of constipation, diarrhea, and food allergy/intolerance.

133 six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) within three rand

134 apy on the basis of the predominant symptom (constipation, diarrhoea, pain, or bloating) or combinati

135 ients with cystic fibrosis and other chronic constipation disorders.

136 ntidepressants suffered from abdominal pain, constipation, dizziness, and dry mouth.

137 iving thalidomide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent

138 Headache, constipation, dizziness, vomiting, and dry mouth were al

139 patients in the Reflux, Abdominal pain, and Constipation domains (4.3 [4.2-4.4] vs. 3.5 [3.3-3.7], 3

140 by means of a structured questionnaire or if constipation/drugs used to treat constipation were coded

141 rs have potential therapeutic indications in constipation, dry eye, cholestatic liver diseases, and i

142 stly mild to moderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, h

143 Constipation due to reduced peristalsis is a major side-

144 ion of daily crying time, regurgitation, and constipation during the first 3 months of life.

145 ant demographic covariates, the incidence of constipation, dyspepsia, and GERD was approximately 1.5-

146 ness, dizziness, sensory neuropathy, tremor, constipation, dyspnea, hypoxia, hypokalemia, rash, and e

147 otic dairy product on symptoms in IBS with a constipation element (IBS-Constipation or IBS-Mixed prof

148 in Tg mice reduced ENS aSyn aggregation and constipation, enhanced gut motility, and increased level

149 d sweating, bowel disturbances (diarrhoea or constipation), episodic dry eyes and mouth, hot flashes,

150 When primary care of constipation fails, the patient may need emergency hospi

151 hronic constipation (CC) includes functional constipation (FC) and irritable bowel syndrome with cons

152 ipation (IBS-C) and patients with functional constipation (FC) have similar symptoms, and these disor

153 Functional constipation (FC) is a common childhood problem often re

154 BACKGROUND & AIMS: Functional constipation (FC) is a common childhood problem often re

155 : irritable bowel syndrome (IBS); functional constipation (FC); functional diarrhea (FDr); functional

156 This issue provides a clinical overview of constipation, focusing on prevention, diagnosis, treatme

157 onic mucosa could discriminate patients with constipation from healthy individuals.

158 globus, rumination syndrome, IBS, bloating, constipation, functional abdominal pain, sphincter of Od

159 zil signal and disease duration, severity of constipation, gastric emptying time, and heart rate vari

160 d clinical information about motor severity, constipation, gastroparesis, and other parameters.

161 ntal defects cause vomiting, abdominal pain, constipation, growth failure, and early death.

162 Those with constipation had a pooled OR of 2.27 (95% CI 2.09 to 2.4

163 Fourteen patients with chronic constipation had slow colonic transit.

164 in a person with either vomiting, diarrhea, constipation, headache, weakness, arthralgia, poor respo

165 oor dysfunction in the absence of functional constipation, however, are prominent in eating disorder

166 ICUs have developed bowel protocols to treat constipation; however, their effect on clinical outcomes

167 lder pain or stiffness), autonomic features (constipation, hypotension, erectile dysfunction, urinary

168 impairment or disorientation, dehydration or constipation, hypoxia, infection, immobility or limited

169 -predominant IBS (IBS-D), mixed-diarrhea-and-constipation IBS (IBS-M), and constipation-predominant (

170 Irritable bowel syndrome with constipation (IBS-C) affects approximately 5% of the pop

171 Patients with irritable bowel syndrome with constipation (IBS-C) and patients with functional consti

172 nd irritable bowel syndrome with predominant constipation (IBS-C) are the 2 most common conditions am

173 ation (FC) and irritable bowel syndrome with constipation (IBS-C).

174 ssociated with irritable bowel syndrome with constipation (IBS-C).

175 Surgery for pediatric idiopathic constipation (IC) is undertaken after failure of bowel m

176 r of emergency hospital separations coded as constipation (ICD-10-AM Code K390).

177 ea reported in 24 (20.5%) and 19 (16.4%) and constipation in 22 (18.8%) and 15 (12.9%) patients treat

178 m was present in 82%, abdominal pain in 49%, constipation in 23% and diarrhea in 22%.

179 olytes (PEG) in the management of functional constipation in adults.

180 olytes are effective and safe treatments for constipation in adults.

181 a decrease in pain, insomnia, anorexia, and constipation in both arms.

182 onic motility, and deficiency of TGR5 causes constipation in mice.

183 Treatment for chronic constipation in older people is challenging and the cond

184 ay contribute to impaired micturition and/or constipation in Parkinson disease and other alpha-synucl

185 w option for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

186 agonist, for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

187 ion continue to have symptoms of diarrhea or constipation in the absence of overt inflammation, indic

188 roaches and limitations in the management of constipation in the older ones to ease the gastroenterol

189 There were 3978 emergency separations for constipation in Victoria in 2010-2011, 92% in public hos

190 ns and the cost to the healthcare system for constipation in Victoria, Australia in financial year 20

191 costs) in managing emergency admissions for constipation in Victoria, Australia, is very significant

192 even, and seven patients, respectively), and constipation (in three, five, four, none, and seven pati

193 rs, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), an

194 umbers of hospital admissions for HD-related constipation increased in recent years from 395 to 340 t

195 lonic mucosal microbiota was associated with constipation, independent of colonic transit (P < .05),

196 with higher rates of thromboembolic events, constipation, infection, and neuropathy than MP.

197 Opioid-induced constipation is a frequent side-effect of opioid treatme

198 Constipation is a frequently reported bowel symptom in t

199 Chronic constipation is a prevalent functional gastrointestinal

200 Functional constipation is a prevalent, burdensome gastrointestinal

201 Constipation is a recognised non-motor feature of Parkin

202 ed success rate of irrigation for functional constipation is about 50 %, comparable to or better than

203 Constipation is common among critically ill patients and

204 Opioid-induced constipation is common and debilitating.

205 Although constipation is not a physiologic consequence of normal

206 to polyethylene glycol for the management of constipation is not established.

207 rates of severe symptoms, including dyspnea, constipation, low appetite, fatigue, depression, and anx

208 id eye movement sleep behavior disorder, and constipation may develop during the prodromal stage of P

209 Restricting analysis to studies assessing constipation more than 10 years prior to Parkinson's dis

210 at least one treatment suggested on chronic constipation, most frequently dietary changes, macrogol

211 in (n = 96; 74.4%), anxiety (n = 77; 59.7%), constipation (n = 69; 53.5%), depression (n = 64; 49.6%)

212 Constipation, nausea, fatigue, and vomiting were the mos

213 patients do not meet these criteria (No Rome Constipation, NRC).

214 Constipation, obesity, and hypothyroidism are associated

215 g mice had reduced aSyn aggregation and less constipation, occurring in part by increasing both pro-B

216 icle is a new sixth category, opioid induced constipation (OIC) which is distinct from the functional

217 uld alleviate the symptoms of opioid-induced constipation (OIC) without compromising the analgesic ef

218 r advance in the treatment of opioid-induced constipation (OIC).

219 sition of the fecal microbiota, but not with constipation or colonic transit.

220 s from patients with IBS-D (but not IBS with constipation or controls) had increased levels of MIR29A

221 lon as a result of disease or therapy causes constipation or diarrhea by unknown mechanisms.

222 lon as a result of disease or therapy causes constipation or diarrhea by unknown mechanisms.

223 toms in IBS with a constipation element (IBS-Constipation or IBS-Mixed profile).

224 orders are defined by >2 symptoms of chronic constipation or irritable bowel syndrome with constipati

225 3 per 10-mm visual analog scale) and chronic constipation (OR, 4.5), predicting the combined outcome

226 -mm visual analog scale pain scale], chronic constipation (OR, 4.9), prostatism (OR, 2.9), being marr

227 ominant symptom (IBS with diarrhea, IBS with constipation, or mixed IBS) plays an important role in s

228 s that include large quantities of red meat, constipation, or physical inactivity increase risk for a

229 ile there was no effect of gender, diarrhea, constipation, other chronic diseases and celiac disease

230 al symptom scores for diarrhea (P = 0.0298), constipation (P = 0.0342), abdominal pain (P = 0.0058),

231 8) and less nausea and vomiting (p=0.02) and constipation (p=0.02).

232 reatest effects were observed among IBS with constipation patients with the FAAH CC variant (P = .045

233 lly well, he reported having had progressive constipation, pelvic pressure, and narrow-caliber stools

234 Overall, in adults diagnosed with functional constipation per Rome III criteria, significant heteroge

235 PAC-QOL) in adults diagnosed with functional constipation per Rome III guidelines.

236 ncluding respiratory depression, significant constipation, physical dependence, and, perhaps most imp

237 Thirteen patients with complete CES [8 constipation predominant (group 1) and 5 incontinence pr

238 d-diarrhea-and-constipation IBS (IBS-M), and constipation-predominant (IBS-C) relative to the control

239 tage of individuals with SCN5A mutations had constipation-predominant IBS (31%) than diarrhea-predomi

240 388 subjects (8.4%) and, of these, 26.5% had constipation-predominant IBS (C-IBS), 44.8% alternating

241 etine to 1 carrier of this mutation (who had constipation-predominant IBS) normalized their bowel hab

242 GC-C ligands are used to successfully treat constipation-predominant irritable bowel syndrome and re

243 isorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity

244 received fecal microbiota from patients with constipation presented a reducing in intestinal peristal

245 An 87 years old male with history of chronic constipation presents with severe abdominal pain to the

246 bidities associated with AF included chronic constipation (prevalence 14.2% vs 3.6%), hypothyroidism

247 ymptoms (PAC-SYM), and Patient Assessment of Constipation-Quality of Life (PAC-QOL) in adults diagnos

248 bed sleep, distress, shortness of breath, or constipation) reached a predetermined severity threshold

249 udy colon motility and transit in health and constipation, recent published data which support the ef

250 e with tremor (OR, 2.74; 95% CI, 2.10-3.57), constipation (relative risk [RR], 2.34; 95% CI, 1.55-3.5

251 ptide approved for the treatment of IBS with constipation, relieves constipation and reduces IBS-asso

252 r, causal relationship between dysbiosis and constipation remains poorly understood.

253 ence for its use in adult chronic functional constipation remains unclear.

254 ssociated with a trend toward a reduction in constipation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p =

255 2.6), dyspepsia (RR, 3.3; 95%, 1.4-7.7), and constipation (RR, 2.2; 95% CI, 1.3-3.7).

256 Studies were included if constipation satisfied the Rome II and or III criteria.

257 The mean Cleveland Clinic constipation score, sense of incomplete evacuation (%),

258 vs OFF: 83% [11-100]; P = 0.007) and Wexner constipation scores improved (PRE: median 19 [9-26] vs O

259 In addition, mean constipation scores were significantly higher for the TT

260 Most patients with chronic constipation secondary to ED with rectal hyposensitivity

261 The most common adverse events were fatigue, constipation, sensory neuropathy, and infection; there w

262 e group vs five [19%] in the placebo group), constipation (seven [27%] vs none), and loss of appetite

263 ne patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and indigestion.

264 omic units) and demographic variables, diet, constipation status, colonic transit, and methane produc

265 ut also differences in core symptoms between constipation subtypes of functional constipation and irr

266 This review aimed to describe core constipation symptoms and their frequency patterns among

267 In general, Asian adults perceive constipation symptoms in a similar but not equivalent ma

268 It is not known if frequency patterns of constipation symptoms in adults are different between th

269 otics on gut transit time, stool output, and constipation symptoms in adults with functional constipa

270 ic transit time (CTT), Patient Assessment of Constipation-Symptoms (PAC-SYM), and Patient Assessment

271 nced more severe reflux, abdominal pain, and constipation than did treatment-naive patients.

272 s that TTIL is associated with more pain and constipation than TAMK.

273 tives for both functional and opioid-induced constipation, the development of neuromodulatory techniq

274 In fecal samples from patients with chronic constipation, the microbiota differs from that of health

275 Thus, in addition to chronic constipation, there is greater potential for the therape

276 with respect to cognitive function, dyspnea, constipation, thirst, leg swelling, numbness, dry mouth,

277 articles of patients with chronic functional constipation, treated with TAI as outpatients and publis

278 Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provi

279 e: incidence of adverse events, incidence of constipation, trial withdrawal rate, and patient satisfa

280 [<1%]), hiccups (three [<1%] vs four [<1%]), constipation (two [<1%] vs three [<1%]), and dyspepsia (

281 The most common in the placebo group were constipation (two [2%] patients) and intestinal obstruct

282 of the following symptoms: urinary symptoms, constipation, upper gastrointestinal tract dysfunction,

283 stipation symptoms in adults with functional constipation via a systematic review and meta-analysis o

284 ents were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral oedema.

285 Constipation was not a risk factor.

286 In contrast to morphine, no significant constipation was produced by compound 2 after oral admin

287 Constipation was the dose-limiting toxicity with both ro

288 Mild-to-moderate constipation was the most common adverse event (in 11% o

289 naire or if constipation/drugs used to treat constipation were coded in patient medical records.

290 tion of probiotics in adults with functional constipation were included.

291 ea, flatulence, abdominal pain/cramping, and constipation were most common.

292 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin

293 ients with noncancer pain and opioid-induced constipation were randomly assigned to receive a daily d

294 More severe symptoms (bloating and constipation) were characteristic of patients who report

295 veloped more gut aSyn aggregation as well as constipation, whereas FTY720-treated Tg mice had reduced

296 Chronic constipation which responds poorly to laxatives may resu

297 ith growth failure, developmental delay, and constipation, which improved after treatment with thyrox

298 nt benefitting some patients with functional constipation, which is a chronic refractory condition.

299 aluation of patients with chronic idiopathic constipation who respond inadequately to available laxat

300 and reversing the effects of opioid induced constipation with peripherally acting opioid antagonists